ABBV-428 + nivolumab

ABBV-428 + nivolumab is an experimental combination therapy for advanced solid tumors, investigated in early-phase clinical studies. **ABBV-428** is a first-in-class, bispecific antibody designed to selectively activate CD40 (a costimulatory protein on antigen-presenting cells) in the tumor microenvironment by targeting mesothelin, a protein overexpressed in several cancers. This approach is intended to maximize immune activation within the tumor while limiting systemic toxicity often seen with standard CD40 agonists. **Nivolumab (Opdivo)** is a human IgG4 monoclonal antibody and programmed cell death-1 (PD-1) immune checkpoint inhibitor, approved for various cancers, that prevents tumor-induced immune suppression. The combination is evaluated for potential synergistic antitumor effects: ABBV-428 activates antigen-presenting cells and tumor immunity, while nivolumab enhances T cell-mediated anti-cancer responses by blocking inhibitory PD-1 signaling. Primary developer is AbbVie, with nivolumab developed and supplied by Bristol Myers Squibb. The regimen is administered intravenously.

Other names

ABBV-428 plus nivolumabABBV428 plus nivolumabABBV 428 plus nivolumabABBV-428 + Opdivo